The Inflection Strategy Framework: an explainer
What the ISF is
The Inflection Strategy Framework is a structured review of execution risk at biotech inflection points — across regulatory, clinical, biostatistics, manufacturing, market access, commercial, investor and board functions, not just the organization chart. It asks the questions a seasoned leader in each function would ask, drawn from industry best practice and documented failures, 6–18 months before a Phase 2/3 readout, a PDUFA date, a commercial launch, or a post-approval scale-up.
Most inflection failures are predictable. Few are predicted.
Efficacy decides many outcomes. But three of every four FDA rejection letters published for 2020–2024 involved quality or manufacturing issues, and about one in five late-stage failures is commercial or strategic. Many efficacy failures, too, trace back to execution decisions made long before the readout: how the trial was powered, which endpoint was chosen, whether payers were ever asked. Those decisions leave signals early.
Sources: Pharma Manufacturing analysis of FDA complete response letters; Hwang et al., JAMA Internal Medicine.
The architecture
The framework is organized into four building blocks. The 27 domains comprise 16 core diagnostic domains, plus seed and monitoring domains that track emerging risks such as trade policy, M&A readiness and loss of exclusivity.
The functional areas where execution risk lives — from leadership alignment through regulatory, manufacturing, market access, pharmacovigilance, AI governance, post-approval recalibration, and capital markets.
Each domain breaks into focused sub-domains that isolate a specific failure surface, such as executive team coherence, clinical-commercial integration, or alliance dependence risk.
Each traces to industry best practice or a documented failure, and each carries a red-flag threshold — the observable condition that signals the risk is present rather than theoretical.
Documented historical failure modes, organized into 31 pattern libraries, each with a root-cause mechanism, an earliest detection point, and a trigger case: either a named company event or a pattern documented across multiple companies.
How an analysis works
- Define the inflection. Identify exactly which moment the company is approaching — readout, PDUFA, launch, or scale-up. The risk profile is different for each.
- Ask and test. Interview leaders at three levels — CEO and board, C-suite, VP — test each answer against its red-flag threshold, rate each domain Elevated, Watch or Clear, and surface the three to five highest-risk areas for this specific company and asset.
- Find the seams. The most diagnostic failures sit at the handoffs between functions — the seam between pharmacovigilance signal detection and clinical's protocol-amendment decision, for example — not inside any single domain.
- Match to the pattern library. Confirm or rule out documented failure modes against the observable evidence.
Why the seams matter most
A company can staff every function competently and still fail at the points where those functions hand work to each other under load. A recurrent serious adverse event gets evaluated in isolation because no governance process requires escalation from monitoring to protocol amendment. A hub vendor gets selected on cost because patient services was treated as procurement rather than access strategy. A commercial team inherits clinical-stage decision cadence with no named authority to change it.
These are the failures the framework is built to catch before the inflection moment arrives, when they are still correctable.
The question at the center
Every engagement reduces to one question for the company facing it: the capabilities that got the organization to this milestone are not always the capabilities required to succeed past it. The framework makes that gap visible while there is still time to close it.
Approaching an inflection point and want an outside view of your inflection risk?
Start a conversation